Biogen's Alzheimer's drug Aduhelm faces EU rejection

Biogen hasn't won support to have its Alzheimer's treatment Aduhelm marketed in the EU, as the drug has received a negative opinion in a trend vote from the EMA's expert committee, the CHMP. The formal rejection of Biogen's marketing authorization application is expected in December.
Photo: POOL New/VIA REUTERS / X80003
Photo: POOL New/VIA REUTERS / X80003
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

The controversial approval of Biogen's drug Aduhelm (aducanumab) in the US hasn't been followed by a corresponding approval in the EU, the company itself reports in a press release on Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading